Download presentation
Presentation is loading. Please wait.
Published byJared Morton Modified over 5 years ago
1
Epstein-Barr Virus–Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes Lan-Ping Xu, Chun-Li Zhang, Xiao-Dong Mo, Xiao-Hui Zhang, Huan Chen, Wei Han, Yu-Hong Chen, Yu Wang, Chen-Hua Yan, Jing-Zhi Wang, Feng-Rong Wang, Ting Zhao, Yan-Rong Liu, Kai-Yan Liu, Xiao-Jun Huang Biology of Blood and Marrow Transplantation Volume 21, Issue 12, Pages (December 2015) DOI: /j.bbmt Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions
2
Figure 1 Kaplan-Meier estimates of overall survival for (A) non-PTLD and (B) PTLD probable and proven PTLD patients. Biology of Blood and Marrow Transplantation , DOI: ( /j.bbmt ) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions
3
Figure 2 Kaplan–Meier estimates of overall survival for PTLD patients treated with (A) rituximab- and non–rituximab-based therapy; (B) rituximab ± DLI therapy, rituximab alone versus DLI alone: P = .015; rituximab alone versus DLI plus rituximab: P = .036; rituximab versus non-rituximab/non-DLI: P = .062. Biology of Blood and Marrow Transplantation , DOI: ( /j.bbmt ) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.